Skip to main content
Larimar Therapeutics, Inc. logo

Larimar Therapeutics, Inc. — Investor Relations & Filings

Ticker · LRMR ISIN · US98885E1038 LEI · 529900NCBZHTTJV6HX73 US Professional, scientific and technical activities
Open in API
Filings indexed 666 across all filing types
Latest filing 2020-02-14 Major Shareholding Noti…
Country US United States of America
Listing US LRMR

About Larimar Therapeutics, Inc.

https://larimartx.com/

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company utilizes a proprietary intracellular delivery platform to design fusion proteins that deliver therapeutic molecules to targets within cells. Its lead product candidate, nomlabofusp (formerly CTI-1601), is a recombinant fusion protein being evaluated in a Phase 2 clinical program for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics plans to leverage its platform to develop additional therapies for other rare diseases characterized by deficiencies in intracellular proteins.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2020
Major Shareholding Notification
2020-02-14 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-02-14 English
AMENDMENT NO. 1 TO THE SCHEDULE 13G
Major Shareholding Notification
2020-02-13 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-02-12 English
SC 13G
Major Shareholding Notification
2020-02-11 English
DEFA14A
Remuneration Information Classification · 100% confidence The document is a Schedule 14A filing, which is a proxy statement or solicitation material related to shareholder voting matters. It includes detailed information about a proposed merger between Zafgen, Inc. and Chondrial Therapeutics, including forward-looking statements, merger terms, and investor presentation content. The document explicitly states it is a proxy statement pursuant to Section 14(a) of the Securities Exchange Act of 1934 and is soliciting proxies from stockholders for the merger approval. It is not an annual report, earnings release, or other financial report but rather a solicitation/proxy statement. The filing type code that best fits this document is "DEF 14A" which corresponds to Remuneration Information and proxy statements filed under Schedule 14A. The confidence in this classification is very high given the explicit SEC form name and content.
2020-02-05 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.